Is It Too Late To Consider Eli Lilly After Its Massive Five Year Share Price Surge?
If you are wondering whether Eli Lilly is still worth buying after its massive run or if the best days are already priced in, you are not alone, and that is exactly what we are going to unpack here.
The stock has pulled back around 8.1% over the last week, but it is still up 11.9% over the past month, 30.4% year to date, and 564.0% over five years, which says a lot about how the market views its long term growth story.
Recently, the spotlight has stayed firmly on Eli Lilly thanks to ongoing excitement around its obesity and diabetes treatment pipeline, as well as expanding approvals that continue to reinforce its leadership in these high demand areas. At the same time, investors are closely watching how supply constraints, capacity expansions, and regulatory decisions might shape the company’s growth runway from here.
Despite that enthusiasm, Eli Lilly scores only 2 out of 6 on our valuation checks. In this article, we will walk through what different valuation approaches indicate about the stock and then finish by looking at a more insightful way to think about its worth beyond the usual models.
Eli Lilly scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.
A Discounted Cash Flow model estimates what a company is worth by projecting its future cash flows and then discounting those back into today’s dollars. For Eli Lilly, the latest twelve month Free Cash Flow stands at roughly $6.2 billion, giving us a solid starting point for those projections.
Analysts see Eli Lilly’s Free Cash Flow rising sharply over the next decade, with projections reaching about $37.6 billion by 2029 and extrapolated estimates climbing above $60 billion by 2035. Simply Wall St uses a two stage Free Cash Flow to Equity approach, combining analyst forecasts for the first few years with gradually slowing growth assumptions afterward to reflect a more mature phase.
When all those future cash flows are discounted back, the model arrives at an intrinsic value of about $1,274 per share. That implies the stock trades at roughly a 20.4% discount to its estimated fair value, which suggests the market is still not fully pricing in Eli Lilly’s long term cash generation potential.
For profitable companies like Eli Lilly, the price to earnings, or PE, ratio is a useful way to judge valuation because it ties the share price directly to the profits the business is generating today. In simple terms, the higher the expected growth and the lower the perceived risk, the more investors are usually willing to pay for each dollar of earnings.
Eli Lilly currently trades at around 49.33x earnings, which is well above the Pharmaceuticals industry average of about 19.72x and also higher than the broader peer group average of roughly 16.25x. On those simple comparisons, the stock looks expensive. However, Simply Wall St also calculates a Fair Ratio of 42.80x, which is the PE multiple the company might reasonably trade at given its specific earnings growth outlook, profitability, industry, size, and risk profile.
This Fair Ratio is more informative than a plain peer or industry comparison because it adjusts for Eli Lilly’s superior growth pipeline and margins, rather than assuming all drug makers deserve the same multiple. With the market PE at 49.33x compared to a Fair Ratio of 42.80x, the shares appear somewhat ahead of fundamentals on this metric.
Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple framework that lets you tell the story behind your numbers by connecting your assumptions about Eli Lilly’s future revenue, earnings, and margins to a clear fair value estimate.
A Narrative on Simply Wall St is your personal storyline for a company, where you spell out what you think will drive its growth, translate that view into a financial forecast, and then see what price those assumptions imply, so the story, the forecast, and the valuation are always linked.
On the Simply Wall St Community page, millions of investors use Narratives as an easy, accessible tool to inform their decisions by comparing their Fair Value to the live share price. Those Narratives automatically update as new earnings, news, or regulatory developments come in, keeping the story and the numbers in sync.
For Eli Lilly, for example, one Narrative currently puts fair value at about $1,189 per share while another sits closer to $1,024. This shows how two reasonable perspectives on growth, margins, and risk can lead to different yet transparent valuation views you can compare directly to today’s price.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
